{"summary": "GS-5734 is a novel nucleotide analog prodrug in the development for treatment of EBOV. antiviral activity of GS-5734 has been established in vitro against a wide range of pathogenic RNA virus families. this includes filoviruses, coronaviruses, and paramyxoviruses. GS-5734 is currently being tested in a phase 2 study in male Ebola survivors with persistent viral RNA in semen. it is a broad-spectrum antiviral to treat viral infections with high mortality and significant outbreak potential."}